Trimodality Therapy With or Without Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
- 1 August 2021
- journal article
- research article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 19 (4) , 362-368
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Cancer Institute (P30CA138292)
- American College of Surgeons
- Winship Cancer Institute
This publication has 21 references indexed in Scilit:
- Bladder Preservation StrategiesHematology/Oncology Clinics of North America, 2015
- Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder CancerNew England Journal of Medicine, 2012
- International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 TrialJournal of Clinical Oncology, 2011
- Comparison of Commission on Cancer–Approved and –Nonapproved Hospitals in the United States: Implications for Studies That Use the National Cancer Data BaseJournal of Clinical Oncology, 2009
- The National Cancer Data Base: A Powerful Initiative to Improve Cancer Care in the United StatesAnnals of Surgical Oncology, 2008
- Neoadjuvant Cisplatinum Based Combination Chemotherapy in Patients with Invasive Bladder Cancer: A Combined Analysis of Two Nordic StudiesEuropean Urology, 2004
- Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder CancerNew England Journal of Medicine, 2003
- Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysisThe Lancet, 2003
- Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03.Journal of Clinical Oncology, 1998
- Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802.Journal of Clinical Oncology, 1996